IVEVF — Inventiva S.A.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1756594 ·
Last close
$3.22
Market Cap
$760.63M
52W High
$5.75
52W Low
$2.28
ADV30
253
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | — | — | — | — | 249,511,000 | 99,312,000 | 278,033,000 |
| Jun 2025 | — | — | — | — | 178,955,000 | 122,076,000 | 187,863,000 |
| Dec 2024 | — | — | — | — | 118,967,000 | 96,563,000 | 225,613,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-354,138,000
Inventory
$0
Receivables
$9,121,000
ST Investments
$131,558,000
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$6,761,000
EBITDA
$-132,497,000
Free Cash Flow
$-200,711,632
Enterprise Value
$876,720,832
Total Cash
$99,839,000
Total Debt
$230,890,000
Shares Out
236,220,651
Trailing EPS
$-2.21
Book Value
$-0.17
ROE
—
ROA
-45.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 4,483,000 | -132,883,000 | -354,138,000 | 249,511,000 | 278,033,000 | -28,522,000 | -104,884,000 |
| Dec 2024 | 9,198,000 | -93,989,000 | -184,212,000 | 118,967,000 | 225,613,000 | -106,646,000 | -85,928,000 |
| Dec 2023 | 17,477,000 | -102,665,000 | -110,426,000 | 69,561,000 | 101,592,000 | -32,031,000 | -81,614,000 |
| Dec 2022 | 12,179,000 | -56,857,000 | -54,274,000 | 116,004,000 | 70,528,000 | 45,476,000 | -44,928,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.06
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ANNX | Annexon, Inc. | $760.21M | $4.01 | — |
| PAHC | PHIBRO ANIMAL HEALTH CORP | $753.47M | $35.70 | — |
| OLMA | Olema Pharmaceuticals, Inc. | $753.35M | $8.61 | — |
| DSGN | Design Therapeutics, Inc. | $773.51M | $12.36 | — |
| SLNCF | Silence Therapeutics plc | $745.85M | $4.00 | — |
News headlines (Yahoo Finance, 1h cache)
Inventiva SA (IVEVF) (H1 2026) Earnings Call Highlights: Lanifibranor Nears Phase 3 Readout ...
2026-09-28 19:00 · Yahoo
Inventiva Q2 Earnings Call Highlights
2026-09-28 14:02 · Yahoo
Inventiva Reports Unaudited 2026 First-Half Financial Results and Provides Corporate Update
2026-09-28 06:00 · Yahoo
Inventiva to Present Multiple Abstracts at Paris MASH 2026
2026-09-08 20:00 · Yahoo
Inventiva Announces Last Patient Visit in NATiV3 Phase 3 Clinical Trial of Lanifibranor in MASH
2026-09-02 20:05 · Yahoo
Chris Benecchi Named Inventiva’s New Chief Operating Officer
2026-08-31 22:08 · Yahoo
Inventiva Appoints Chris Benecchi as Chief Operating Officer
2026-08-31 20:05 · Yahoo
Claret Capital Partners provides €30m financing to Carvolix to accelerate commercialization of medtech portfolio
2026-08-06 11:00 · Yahoo
Inventiva (ENXTPA:IVA) Puts Its MASH Narrative To The Test After A Recent Rebound
2026-07-12 13:08 · Yahoo
Inventiva Announces Completion of the EIB Warrant Restructuring with the Issuance of New EIB Warrants
2026-07-09 20:20 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.